|Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D.||CEO & Exec. Director||540k||N/A||1963|
|Mr. Paul Leslie Stockdale F.C.A., M.A.||CFO & Exec. Director||205.97k||N/A||1975|
|Dr. Alexandre Akoulitchev M.A., Ma (Oxon), Ph.D.||Chief Scientific Officer & Exec. Director||229.45k||N/A||1962|
|Mr. Thomas G. Guiel B.A.||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Ewan Hunter B.Sc., BSC, Ph.D., Ph.D., (KCL)||Chief Data Officer||N/A||N/A||N/A|
|T. Demain||Company Sec.||N/A||N/A||N/A|
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Oxford BioDynamics Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.